



(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/47 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/EP2017/081800

(22) International Filing Date:

07 December 2017 (07.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10 2016 123 847.3

08 December 2016 (08.12.2016) DE

62/431,588 08 December 2016 (08.12.2016) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH

[DE/DE]; Paul-Ehrlich-Straße 15, 72076 Tübingen (DE).


(72) Inventors: **ALTEN, Leonie**; Weißdornweg 14, App. 161, 72076 Tübingen (DE). **BUNK, Sebastian**; Gertrud-Baeumer-Str. 19/1, 72074 Tübingen (DE). **MAURER, Dominik**; Fleinerweg 7, 72116 Moessingen (DE). **WAGNER, Claudia**; Nürtinger Strasse 32, 72074 Tübingen (DE).

(74) Agent: **BOEHMERT & BOEHMERT**; KRAUSS, Jan B., Pettenkoferstrasse 22, 80336 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME

Figure 1:



(57) **Abstract:** The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

[Continued on next page]



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*